# Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

> **NCT05956522** · PHASE1 · COMPLETED · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 106 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Test Empagliflozin And Linagliptin Tablets
- **DRUG:** Reference Empagliflozin And Linagliptin tablets

## Key facts

- **NCT ID:** NCT05956522
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2022-11-23
- **Final completion:** 2023-01-13
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05956522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05956522, "Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05956522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*